Diatide signs license deal with Angstrom
Radiopharmaceutical firm Diatide last month signed a license agreement with Angstrom Pharmaceuticals that will allow Angstrom to develop cancer-fighting pharmaceuticals. Londonderry, NH-based Diatide will have global exclusive rights to imaging and
Radiopharmaceutical firm Diatide last month signed a license agreement with Angstrom Pharmaceuticals that will allow Angstrom to develop cancer-fighting pharmaceuticals. Londonderry, NH-based Diatide will have global exclusive rights to imaging and therapeutic agents produced from Angstroms tumor-targeting technology. Diatide will pay San Diego-based Angstrom an initial payment, future research and milestone payments, and royalties on product sales, and will provide research support.
Angstrom has developed and patented small cyclic peptides that bind to a key receptor found on the surface of almost all solid tumors, including breast, prostate, colon, and lung. The two firms believe that targeting these receptors with radiotherapeutic agents could obstruct tumor growth.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
